|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2010-8-23
|
|
pubmed:abstractText |
Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated its safety and efficacy in patients with relapsed/refractory follicular lymphoma (FL) after prior rituximab therapy. Design and methods: Forty-seven patients were treated in three dose cohorts and received eight infusions every 3 weeks: cohort A, 200 mg/m(2) (n = 15); cohort B, 375 mg/m(2) (n = 16); cohort C, first dose 375 mg/m(2), seven subsequent doses of 750 mg/m(2) (n = 16). Patients were assessed for safety, efficacy, pharmacodynamics and pharmacokinetics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:BrennanBB,
pubmed-author:BurgerH-UHU,
pubmed-author:CoiffierBB,
pubmed-author:CrumpMM,
pubmed-author:FryHH,
pubmed-author:LindénOO,
pubmed-author:MarltonPP,
pubmed-author:MendilaMM,
pubmed-author:MorschhauserFF,
pubmed-author:SeymourJ FJF,
pubmed-author:VitoloUU,
pubmed-author:WassnerEE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1870-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20157180-Adult,
pubmed-meshheading:20157180-Aged,
pubmed-meshheading:20157180-Aged, 80 and over,
pubmed-meshheading:20157180-Antibodies, Monoclonal,
pubmed-meshheading:20157180-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20157180-Antigens, CD20,
pubmed-meshheading:20157180-Drug Resistance, Neoplasm,
pubmed-meshheading:20157180-Female,
pubmed-meshheading:20157180-Follow-Up Studies,
pubmed-meshheading:20157180-Humans,
pubmed-meshheading:20157180-Lymphoma, Follicular,
pubmed-meshheading:20157180-Male,
pubmed-meshheading:20157180-Middle Aged,
pubmed-meshheading:20157180-Neoplasm Recurrence, Local,
pubmed-meshheading:20157180-Neoplasm Staging,
pubmed-meshheading:20157180-Remission Induction,
pubmed-meshheading:20157180-Salvage Therapy,
pubmed-meshheading:20157180-Survival Rate,
pubmed-meshheading:20157180-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.
|
|
pubmed:affiliation |
Department of Hematology, Claude Huriez Hospital, Lille, France. franck.morschhauser@chru-lille.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
